Your browser doesn't support javascript.
loading
Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors.
Palumbo, Carlotta; Mistretta, Francesco A; Mazzone, Elio; Knipper, Sophie; Tian, Zhe; Perrotte, Paul; Antonelli, Alessandro; Montorsi, Francesco; Shariat, Shahrokh F; Saad, Fred; Simeone, Claudio; Briganti, Alberto; Lattouf, Jean-Baptiste; Karakiewicz, Pierre I.
Affiliation
  • Palumbo C; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. Electronic address
  • Mistretta FA; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, European Institute of Oncology, Milan, Italy.
  • Mazzone E; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Martini Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Knipper S; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Division of Experimental Oncology/Unit of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy, and Vita-Salute San Raffaele University, Milan,
  • Tian Z; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Perrotte P; Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, Quebec, Canada.
  • Antonelli A; Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.
  • Montorsi F; Martini Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Shariat SF; Department of Urology, Medical University of Vienna, Vienna, Austria.
  • Saad F; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, Quebec, Canada.
  • Simeone C; Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.
  • Briganti A; Martini Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Lattouf JB; Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, Quebec, Canada.
  • Karakiewicz PI; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, Quebec, Canada.
Clin Genitourin Cancer ; 17(5): e1026-e1035, 2019 10.
Article in En | MEDLINE | ID: mdl-31378580
ABSTRACT

BACKGROUND:

We comprehensively tested contemporary incidence and mortality rates in patients with germ cell tumor of the testis (GCTT). MATERIALS AND

METHODS:

Within the Surveillance, Epidemiology, and End Results database (2004-2015), statistical analyses included estimated annual percentage changes, multivariable logistic regression (MLR) models, Kaplan-Meier curves, and multivariable Cox regression (MCR) models.

RESULTS:

Of 13,114 GCTT patients, 7954 (60.6%) harbored seminoma germ cell tumors of the testis (SGCTT) and 5160 (39.4%) non-SGCTT (NSGCTT). Relative to SGCTT, NSGCTT patients harbored more advanced stage (for stage III 824 [16.0%] vs. 279 patients [3.5%]; P < .001). In MLR, higher rates of stage II/III affected those with never-married status (odds ratio [OR], 1.6; P < .001) and African American ethnicity (OR, 1.5; P = .005) for SGCTT and never-married (OR, 1.3; P = .002) and Hispanic ethnicity (OR, 1.3; P < .001) for NSGCTT. Significant differences in 5-year cancer-specific mortality (CSM) distinguished SGCTT (stage I 0.4; stage II 3.4; stage III 11.4%; P < .001) from NSGCTT (stage I 1.6; stage II 2.5; stage III 22.2%; P < .001). In MCR, unmarried status independently predicted higher CSM for SGCTT (hazard ratio [HR], 2.1; P = .007) and NSGCTT (HR, 1.9; P < .001).

CONCLUSION:

Stage I and stage III NSGCTT survival is worse, than for SGCTT. Never-married, Hispanic, and African American individuals are at higher risk of more advanced stage and/or CSM in SGCTT and NSGCTT.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Testicular Neoplasms / Seminoma / Neoplasms, Germ Cell and Embryonal Type of study: Incidence_studies / Prognostic_studies Limits: Adult / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Clin Genitourin Cancer Journal subject: NEOPLASIAS / UROLOGIA Year: 2019 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Testicular Neoplasms / Seminoma / Neoplasms, Germ Cell and Embryonal Type of study: Incidence_studies / Prognostic_studies Limits: Adult / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Clin Genitourin Cancer Journal subject: NEOPLASIAS / UROLOGIA Year: 2019 Document type: Article